Western Wealth Management’s AbbVie ABBV Stock Holding History

Western Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.01M	Buy	36,815 +13,001	+55%	+$2.88M	0.3%	59
2025 Q4	$5.44M	Buy	23,814 +1,985	+9%	+$452K	0.25%	73
2025 Q3	$5.05M	Buy	21,829 +85	+0.4%	+$17.3K	0.27%	74
2025 Q2	$4.04M	Buy	21,744 +252	+1%	+$46.8K	0.24%	88
2025 Q1	$4.5M	Buy	21,492 +137	+0.6%	+$26.6K	0.3%	73
2024 Q4	$3.79M	Sell	21,355 -14,741	-41%	-$2.71M	0.25%	79
2024 Q3	$7.13M	Buy	36,096 +15,299	+74%	+$2.86M	0.41%	47
2024 Q2	$3.57M	Buy	20,797 +539	+3%	+$89.3K	0.26%	76
2024 Q1	$3.69M	Sell	20,258 -15,061	-43%	-$2.6M	0.29%	74
2023 Q4	$5.47M	Sell	35,319 -2,002	-5%	-$292K	0.39%	50
2023 Q3	$5.56M	Buy	37,321 +1,075	+3%	+$158K	0.47%	41
2023 Q2	$4.88M	Sell	36,246 -1,706	-4%	-$250K	0.42%	43
2023 Q1	$6.05M	Buy	37,952 +4,509	+13%	+$689K	0.56%	33
2022 Q4	$5.4M	Sell	33,443 -21,821	-39%	-$3.35M	0.55%	36
2022 Q3	$7.6M	Sell	55,264 -246	-0.4%	-$35.3K	0.44%	42
2022 Q2	$8.5M	Sell	55,510 -1,124	-2%	-$172K	0.49%	40
2022 Q1	$9.18M	Buy	56,634 +33,597	+146%	+$4.88M	0.45%	41
2021 Q4	$3.12M	Buy	+23,037	New	+$2.72M	0.31%	67
2021 Q2	$3.29M	Buy	29,172 +11,255	+63%	+$1.27M	0.34%	64
2021 Q1	$1.94M	Buy	17,917 +672	+4%	+$71.9K	0.26%	86
2020 Q4	$1.85M	Sell	17,245 -359	-2%	-$34.5K	0.27%	89
2020 Q3	$1.54M	Buy	17,604 +1,285	+8%	+$121K	0.25%	100
2020 Q2	$1.6M	Buy	16,319 +4,529	+38%	+$399K	0.29%	82
2020 Q1	$901K	Buy	11,790 +3,416	+41%	+$291K	0.21%	115
2019 Q4	$741K	Buy	8,374 +448	+6%	+$37.2K	0.11%	173
2019 Q3	$605K	Sell	7,926 -1,931	-20%	-$132K	0.13%	185
2019 Q2	$715K	Sell	9,857 -1,295	-12%	-$102K	0.09%	171
2019 Q1	$900K	Buy	11,152 +217	+2%	+$17.8K	0.2%	126
2018 Q4	$1.01M	Buy	+10,935	New	+$962K	0.27%	87

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Western Wealth Management's ABBV Position: Q1 2026 in Review

Western Wealth Management increased its AbbVie (ABBV) stake by 55% in Q1 2026, buying an estimated $2.88M and bringing the position to 36,815 shares worth $8.01M. The position accounts for 0.3% of the portfolio, ranked #59.

Western Wealth Management first reported a position in ABBV in Q4 2018 and has held it in 29 quarters since. The position peaked at $9.18M in Q1 2022. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Western Wealth Management held 36,815 shares of AbbVie worth $8.01M as of Q1 2026.
Western Wealth Management bought 13,001 AbbVie shares in Q1 2026, an estimated $2.88M.
AbbVie made up 0.3% of Western Wealth Management's portfolio in Q1 2026, its #59 holding.
Western Wealth Management first reported a position in AbbVie in Q4 2018 and has held it in 29 quarters since.
Western Wealth Management's AbbVie position peaked at $9.18M in Q1 2022.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Western Wealth Management's 13F filing for Q1 2026, filed 19 May 2026.